0001333493-23-000006.txt : 20230124 0001333493-23-000006.hdr.sgml : 20230124 20230124164750 ACCESSION NUMBER: 0001333493-23-000006 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230124 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230124 DATE AS OF CHANGE: 20230124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: eHealth, Inc. CENTRAL INDEX KEY: 0001333493 STANDARD INDUSTRIAL CLASSIFICATION: INSURANCE AGENTS BROKERS & SERVICES [6411] IRS NUMBER: 770470789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33071 FILM NUMBER: 23548699 BUSINESS ADDRESS: STREET 1: 2625 AUGUSTINE DRIVE, SUITE 150 CITY: SANTA CLARA STATE: CA ZIP: 95054 BUSINESS PHONE: 650-584-2700 MAIL ADDRESS: STREET 1: 2625 AUGUSTINE DRIVE, SUITE 150 CITY: SANTA CLARA STATE: CA ZIP: 95054 8-K 1 ehth-20230124.htm 8-K ehth-20230124
FALSE000133349300013334932023-01-242023-01-24


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): January 24, 2023
EHEALTH, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware001-3307156-2357876
(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

2625 AUGUSTINE DRIVE, SUITE 150
SANTA CLARA, CA 95054
(Address of principal executive offices)    (Zip Code)

(650) 210-3150
(Registrant’s telephone number, including area code)

Not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareEHTHThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨




Item 2.02Results of Operations and Financial Condition.

On January 24, 2023, eHealth, Inc. (the “Company”) issued a press release announcing preliminary results for the fourth quarter and fiscal year ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Item 2.02 of this Current Report on Form 8-K and the exhibit attached hereto is intended to be “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Except as shall be expressly set forth by specific reference in such filing, the information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


Item 9.01 Financial Statements and Exhibits.

(d)    Exhibits
Exhibit No.Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)





SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
eHealth, Inc.
Date:January 24, 2023/s/ John Stelben
John Stelben
Chief Financial Officer
(Principal Financial Officer)





EX-99.1 2 ex9912022yepre-release.htm EX-99.1 Document
logoa.jpg


eHealth, Inc. Announces Preliminary Results for the Fourth Quarter and Fiscal Year 2022
Fourth quarter performance reflects significant increase in productivity of eHealth’s telesales operations

SANTA CLARA, California, January 24, 2023 eHealth, Inc. (Nasdaq: EHTH), a leading private online health insurance marketplace, today announced preliminary, unaudited financial results and select operating metrics for the fourth quarter and fiscal year ended December 31, 2022.

“eHealth’s fourth quarter results reflect the transformational initiatives that we implemented in 2022 across all key areas of the company. During the fourth quarter Annual Enrollment Period, our company helped thousands of Americans shop for and enroll in healthcare plans that we believe represent an optimal match for them based on their personal preferences, healthcare needs, and budgets. We were able to do so while exceeding our cost reduction goals and significantly improving the efficiency of our sales and marketing organizations by emphasizing our most profitable marketing channels and enhancing agent productivity,” said Fran Soistman, chief executive officer of eHealth. "The Medicare market remains strong, reflecting a robust selection of quality plans, significant customer demand, and a more rational approach to enrollment growth by our peers that emphasizes profitability over growth-at-all-costs. eHealth ended 2022 with a strong cash position, and we expect to deliver further meaningful improvements to our operational and financial performance in 2023. We look forward to providing full fourth quarter and fiscal year 2022 results as well as our 2023 guidance on our upcoming fourth quarter earnings call."

Fourth Quarter and Fiscal Year 2022 Preliminary Results

Revenue for the fourth quarter of 2022 is expected to be in the range of $190 to $200 million. Revenue for the year ended December 31, 2022 is expected to be in the range of $395 to $405 million as compared to the company’s guidance of $375 to $395 million.

GAAP net income for the fourth quarter of 2022 is expected to be in the range of $16 to $21 million. GAAP net loss for the year ended December 31, 2022 is expected to be in the range of $93 to $88 million as compared to the company’s guidance of $115 to $92 million.

Adjusted EBITDA for the fourth quarter of 2022 is expected to be in the range of $40 to $50 million. Adjusted EBITDA for the year ended December 31, 2022 is expected to be in the range of $(50) to $(40) million as compared to the company’s guidance of $(73) to $(45) million.

Total cash outflow for the year ended December 31, 2022 (excluding the impact of our $70 million term loan and associated costs and net securities activities) is expected to be $44 million as compared to the company’s guidance of $110 to $90 million.

Select Operating Metrics
The company exceeded its cost reduction goals for the full year 2022 by delivering over $110 million in net operating cost savings compared to the full year 2021.

Fourth quarter of 2022 telephonic conversion rates in the company’s Medicare business improved by more than 25% compared to the fourth quarter of 2021.

Medicare Advantage Approved Applications for the fourth quarter of 2022 were 131,235, a decline of 26% year-over-year. Medicare Advantage Approved Applications for the year ended December 31, 2022 were 302,949, a decline of 24% year-over-year. Decline in approved applications reflects a significant reduction in marketing costs in 2022 compared to 2021, which was partially offset by an increase in agent productivity.

The preliminary, unaudited financial results and select operating metrics included in this press release are based on information available as of January 24, 2023 and management's initial review of operations for the fourth quarter and year ended December 31, 2022. They remain subject to change based on management's ongoing review of the Company's fourth-quarter and full year results and are forward-looking statements. eHealth assumes no obligation to update these
1


statements. The actual results may be materially different and are affected by the risk factors and uncertainties identified in this press release and in eHealth's annual and quarterly filings with the Securities and Exchange Commission.

About eHealth

For more than 25 years, eHealth, Inc. (Nasdaq: EHTH) has served American consumers with innovative technology and licensed agent support to help them find health insurance solutions that fit their personal needs. Through its proprietary health insurance marketplace at eHealth.com and eHealthMedicare.com, eHealth has connected more than eight million members with quality, affordable coverage. eHealth offers Medicare Advantage, Medicare Supplement, Medicare Part D, individual, family, small business, and ancillary plans from approximately 200 health insurance companies nationwide.

Forward-Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. These include statements regarding factors that impacted our fourth quarter performance; our expected cost savings; our expected operating and financial performance in 2023; our expected revenue, GAAP net income (loss), Adjusted EBITDA and total cash outflow for the fourth quarter of 2022 and the year ended December 31, 2022; our operating cost savings in 2022; our telephonic conversion rates in our Medicare business in the fourth quarter of 2022; and our Medicare Advantage Approved Applications for the fourth quarter of 2022.

These forward-looking statements are inherently subject to various risks and uncertainties that could cause actual results to differ materially from the statements made. In particular, we are required by Accounting Standards Codification 606 — Revenue from Contracts with Customers to make numerous assumptions that are based on historical trends and our management’s judgment. These assumptions may change over time and have a material impact on our revenue recognition, guidance, and results of operations. Please review the assumptions stated in this press release carefully.

The risks and uncertainties that could cause our results to differ materially from those expressed or implied by such forward-looking statements include our ability to retain existing members and enroll new members during the annual health care open enrollment period, the Medicare annual enrollment period and other special enrollment periods; changes in laws, regulations and guidelines, including in connection with health care reform or with respect to the marketing and sale of Medicare plans; competition, including competition from government-run health insurance exchanges and other sources; the seasonality of our business and the fluctuation of our operating results; our ability to accurately estimate membership, lifetime value of commissions and commissions receivable; changes in product offerings among carriers on our ecommerce platform and the resulting impact on our commission revenue; our ability to execute on our growth strategy in the Medicare market; the impact of the COVID-19 pandemic and other public health crises, illness, epidemics or pandemics on our operations, business, financial condition and growth prospects, as well as on the general economy; changes in our management and key employees; exposure to security risks and our ability to safeguard the security and privacy of confidential data; our relationships with health insurance carriers; the success of our carrier advertising and sponsorship program; our success in marketing and selling health insurance plans and our unit cost of acquisition; our ability to hire, train, retain and ensure the productivity of licensed health insurance agents and other employees; our ability to effectively manage our operations as our business evolves and execute on our transformational plan and other strategic initiatives; the need for health insurance carrier and regulatory approvals in connection with the marketing of Medicare-related insurance products; changes in the market for private health insurance; consumer satisfaction of our service and actions we take to improve the quality of enrollments; changes in member conversion rates; changes in commission rates; our ability to sell qualified health insurance plans to subsidy-eligible individuals and to enroll subsidy-eligible individuals through government-run health insurance exchanges; our ability to maintain and enhance our brand identity; our ability to derive desired benefits from investments in our business, including membership growth and retention initiatives; reliance on marketing partners; the impact of our direct-to-consumer mail, email, social media, telephone and television marketing efforts; timing of receipt and accuracy of commission reports; payment practices of health insurance carriers; dependence on our operations in China; the restrictions in our debt obligations; the restrictions in our investment agreement with H.I.G; our ability to raise additional capital; compliance with insurance, privacy and other laws and regulations; the outcome of litigation in which we are and may from time to time be involved; the performance, reliability and availability of our information technology systems, ecommerce platform and underlying network infrastructure; and that our audit leads to changes in the financial results and selected operating metrics included in this press release. Other factors that could cause operating, financial and other results to differ are described in our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on the investor relations page of our website at http://www.ehealthinsurance.com and on the Securities and Exchange Commission’s website at www.sec.gov.

All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
2



Non-GAAP Financial Information
This press release includes Adjusted EBITDA, a financial measure that is not calculated in accordance with generally accepted accounting principles in the United States (GAAP). Adjusted EBITDA is calculated by excluding the impact from preferred stock, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, impairment charges, restructuring charges, amortization of intangible assets, other income (expense), net, and other non-recurring charges from GAAP net income (loss) attributable to common stockholders. Other non-recurring charges to GAAP net income (loss) attributable to common stockholders may include transaction expenses in connection with capital raising transactions (whether debt, equity or equity-linked) and acquisitions, whether or not consummated, purchase price adjustments and the cumulative effect of a change in accounting principles.

eHealth believes that the presentation of Adjusted EBITDA provides important supplemental information to management and investors regarding financial and business trends relating to eHealth’s financial condition and results of operations. Management believes that the use of Adjusted EBITDA provides consistency and comparability with eHealth’s past financial reports. Management also believes that Adjusted EBITDA provides an additional measure of eHealth’s operating results and facilitates comparisons of eHealth’s core operating performance against prior periods and business model objectives. This information is provided to investors in order to facilitate additional analyses of past, present and future operating performance and as a supplemental means to evaluate eHealth’s ongoing operations. eHealth believes that Adjusted EBITDA is useful to investors in their assessment of eHealth’s operating performance.

Adjusted EBITDA is not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Adjusted EBITDA has limitations in that it does not reflect all of the revenue and costs associated with the operations of eHealth’s business and does not reflect income tax as determined in accordance with GAAP. As a result, you should not consider this measure in isolation or as a substitute for analysis of eHealth’s results as reported under GAAP. eHealth expects to continue to incur the stock-based compensation costs and depreciation and amortization described above, and exclusion of these costs, and their related income tax benefits, from Adjusted EBITDA should not be construed as an inference that these costs are unusual or infrequent. eHealth compensates for these limitations by prominently disclosing GAAP net income (loss) and providing investors with a reconciliation from eHealth’s GAAP net income (loss) to Adjusted EBITDA for the relevant periods.

The accompanying table provides more details on GAAP net income (loss), which is the most directly comparable GAAP financial measure to Adjusted EBITDA, a non-GAAP financial measure, and the related reconciliation between these financial measures.

Non-GAAP Financial Information Reconciliation
Three Months Ended
December 31, 2022
Year Ended
December 31, 2022
(in millions, unaudited)LowHighLowHigh
GAAP net income (loss)$16 $21 $(93)$(88)
Stock-based compensation expense19 20 
Depreciation and amortization20 21 
Other expense, net
Impairment, restructuring and other charges10 19 21 
Provision for (benefit from) income taxes(19)(18)
Adjusted EBITDA$40 $50 $(50)$(40)
Investor Relations Contact:
Kate Sidorovich, CFA
Senior Vice President, Investor Relations & Strategy
Kate.Sidorovich@ehealth.com




3
EX-101.SCH 3 ehth-20230124.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ehth-20230124_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 ehth-20230124_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 logoa.jpg begin 644 logoa.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover Page
Jan. 24, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 24, 2023
Entity Registrant Name EHEALTH, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-33071
Entity Tax Identification Number 56-2357876
Entity Address, Address Line One 2625 AUGUSTINE DRIVE, SUITE 150
Entity Address, City or Town SANTA CLARA
Entity Address, State or Province CA
Entity Address, Postal Zip Code 95054
City Area Code 650
Local Phone Number 210-3150
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Pre-commencement Issuer Tender Offer false
Trading Symbol EHTH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001333493
XML 8 ehth-20230124_htm.xml IDEA: XBRL DOCUMENT 0001333493 2023-01-24 2023-01-24 false 0001333493 8-K 2023-01-24 EHEALTH, INC. DE 001-33071 56-2357876 2625 AUGUSTINE DRIVE, SUITE 150 SANTA CLARA CA 95054 650 210-3150 false false false false false false Common Stock, par value $0.001 per share EHTH NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.ehealthinsurance.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports ehth-20230124.htm ehth-20230124.xsd ehth-20230124_lab.xml ehth-20230124_pre.xml ex9912022yepre-release.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ehth-20230124.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "ehth-20230124.htm" ] }, "labelLink": { "local": [ "ehth-20230124_lab.xml" ] }, "presentationLink": { "local": [ "ehth-20230124_pre.xml" ] }, "schema": { "local": [ "ehth-20230124.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ehth", "nsuri": "http://www.ehealthinsurance.com/20230124", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20230124.htm", "contextRef": "i455f891ecaa542f49cc5a2da73f4a382_D20230124-20230124", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.ehealthinsurance.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ehth-20230124.htm", "contextRef": "i455f891ecaa542f49cc5a2da73f4a382_D20230124-20230124", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ehealthinsurance.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001333493-23-000006-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001333493-23-000006-xbrl.zip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end